• Azer-cel Phase 1b trial achieves 82% Overall Response Rate in relapsed/refractory DLBCL patients
• Expansion into CAR T naïve patients showing 83% response rate
• FDA meeting validates critical components of azer-cel strategy

Imugene Limited reported a loss of $37,820,158 for the half year ended 31 December 2025, a 22% reduction compared to the prior corresponding period. This was largely driven by a decrease in personnel-related general and administrative expenditures from a lower headcount, as well as significant reductions in clinical trial and research costs across the R&D pipeline. The company ended the period with cash reserves of $14.1 million. Key highlights include the azer-cel CAR T Phase 1b trial achieving an 82% overall response rate in relapsed/refractory DLBCL patients, with the first patient dosed remaining cancer-free for over 22 months. Imugene also expanded the trial to target CAR T naïve patients in rare lymphoma indications, yielding a 83% response rate. The company received positive feedback from the FDA, validating critical components of the azer-cel strategy. Imugene entered a new collaboration with JW Therapeutics to advance the onCARlytics program, which is expected to reduce capital expenditure. The company also completed a $25 million capital raise and amended its convertible note facility to improve cash flow management.

Operating costs expected to be approximately 50% lower than the prior financial year.